Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jim Bristow, Kevin Cronin, and J. Patrick Ravenel

Premium

Maverix Biomics has added Jim Bristow to its scientific advisory board.

Bristow is currently the deputy of science at the Department of Energy's Joint Genome Institute where he is responsible for developing and implementing the Community Science Program which provides sequencing and analysis for projects of relevance to DOE missions in energy and environment. He also oversees the JGI's plant, fungal, microbial, and metagenome science programs, and manages JGI’s activities as a user facility. In the past, Bristow has been a faculty member at University of California, San Francisco; and has held leadership positions on several grant review boards and advisory committees for the American Heart Association, the National Institutes of Health, and DOE.


Core Informatics has hired Kevin Cronin as its chief commercial officer.

Cronin brings 25 years of experience leading sales and marketing teams serving pharmaceutical, agrochemical, consumer, and chemical companies. He joins Core from Dassault Systemes BIOVIA (formerly Accelrys) where he was most recently vice president of its North American life science division and, prior to that, was Accelrys vice president for global strategic accounts. He's also worked at Symyx and at NextBio — now owned by Illumina.


Cypher Genomics has hired J. Patrick Ravenel as chief technology officer. In the role, he will help advance Cypher's MantisTM, genome interpretation software as a service offering, and CoralTM, a biomarker discovery service.

Previously Ravenel was the vice president of software development at MedImpact Healthcare Systems. Prior to MedImpact, he had successful exits as a co-founder and a director in the areas of security and distributed transactional caching environments. He holds a B.A. in applied mathematics and scientific programming from the University of California, San Diego.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.